Original article
Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experience
Reactivación del virus de la hepatitis B en receptores de trasplante renal con infección previa resuelta clínicamente: una experiencia de un solo centro
Catarina Menga,b,
, Carolina Belinoc, Luciano Pereiraa,b, Ana Pinhoa,b, Susana Sampaioa,b, Isabel Tavaresa,b, Manuela Bustorffa,b, António Sarmentob,d,e, Manuel Pestanaa,b,e
Corresponding author
a Nephrology Department, Centro Hospitalar de São João, Porto, Portugal
b Nephrology and Infecciology Group, INEB/I3S, Porto, Portugal
c Nephrology Department, Centro Hospitalar de Vila Nova de Gaia-Espinho, Vila Nova de Gaia, Portugal
d Infectious Diseases Department, Centro Hospitalar de São João, Porto, Portugal
e Faculty of Medicine of University of Porto, Porto, Portugal
Read
7670
Timeswas read the article
2474
Total PDF
5196
Total HTML
Share statistics
array:25 [ "pii" => "S2013251418301159" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2018.02.013" "estado" => "S300" "fechaPublicacion" => "2018-09-01" "aid" => "476" "copyright" => "Sociedad Española de Nefrología" "copyrightAnyo" => "2018" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2018;38:545-50" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1581 "formatos" => array:3 [ "EPUB" => 163 "HTML" => 932 "PDF" => 486 ] ] "Traduccion" => array:1 [ "en" => array:20 [ "pii" => "S0211699518300419" "issn" => "02116995" "doi" => "10.1016/j.nefro.2018.02.004" "estado" => "S300" "fechaPublicacion" => "2018-09-01" "aid" => "476" "copyright" => "Sociedad Española de Nefrología" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2018;38:545-50" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2616 "formatos" => array:3 [ "EPUB" => 284 "HTML" => 1561 "PDF" => 771 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experience" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "545" "paginaFinal" => "550" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Reactivación del virus de la hepatitis B en receptores de trasplante renal con infección previa resuelta clínicamente: una experiencia de un solo centro" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Catarina Meng, Carolina Belino, Luciano Pereira, Ana Pinho, Susana Sampaio, Isabel Tavares, Manuela Bustorff, António Sarmento, Manuel Pestana" "autores" => array:9 [ 0 => array:2 [ "nombre" => "Catarina" "apellidos" => "Meng" ] 1 => array:2 [ "nombre" => "Carolina" "apellidos" => "Belino" ] 2 => array:2 [ "nombre" => "Luciano" "apellidos" => "Pereira" ] 3 => array:2 [ "nombre" => "Ana" "apellidos" => "Pinho" ] 4 => array:2 [ "nombre" => "Susana" "apellidos" => "Sampaio" ] 5 => array:2 [ "nombre" => "Isabel" "apellidos" => "Tavares" ] 6 => array:2 [ "nombre" => "Manuela" "apellidos" => "Bustorff" ] 7 => array:2 [ "nombre" => "António" "apellidos" => "Sarmento" ] 8 => array:2 [ "nombre" => "Manuel" "apellidos" => "Pestana" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2013251418301159" "doi" => "10.1016/j.nefroe.2018.02.013" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251418301159?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699518300419?idApp=UINPBA000064" "url" => "/02116995/0000003800000005/v1_201810110611/S0211699518300419/v1_201810110611/en/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S2013251418301135" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2018.02.011" "estado" => "S300" "fechaPublicacion" => "2018-09-01" "aid" => "487" "copyright" => "Sociedad Española de Nefrología" "documento" => "simple-article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "crp" "cita" => "Nefrologia (English Version). 2018;38:551-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2669 "formatos" => array:3 [ "EPUB" => 169 "HTML" => 1418 "PDF" => 1082 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case report</span>" "titulo" => "Haemodialysis-related-heparin-induced thrombocytopenia: Case series and literature review" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "551" "paginaFinal" => "557" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Trombocitopenia inducida por heparina en hemodiálisis: serie de casos y revisión de la literatura" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 3323 "Ancho" => 2547 "Tamanyo" => 477301 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Algorithm for the diagnosis and management of immune HD-HIT.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Joana Gameiro, Sofia Jorge, José António Lopes" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Joana" "apellidos" => "Gameiro" ] 1 => array:2 [ "nombre" => "Sofia" "apellidos" => "Jorge" ] 2 => array:2 [ "nombre" => "José António" "apellidos" => "Lopes" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0211699518300651" "doi" => "10.1016/j.nefro.2018.02.010" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699518300651?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251418301135?idApp=UINPBA000064" "url" => "/20132514/0000003800000005/v1_201811140611/S2013251418301135/v1_201811140611/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S2013251418301111" "issn" => "20132514" "doi" => "10.1016/j.nefroe.2018.10.004" "estado" => "S300" "fechaPublicacion" => "2018-09-01" "aid" => "478" "copyright" => "Sociedad Española de Nefrología" "documento" => "article" "crossmark" => 0 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2018;38:535-44" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2149 "formatos" => array:3 [ "EPUB" => 217 "HTML" => 1375 "PDF" => 557 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Carer's burden of peritoneal dialysis patients. Questionnaire and scale validation" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "535" "paginaFinal" => "544" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Sobrecarga de los cuidadores de pacientes de diálisis peritoneal. Validación de cuestionario y baremos" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1169 "Ancho" => 1585 "Tamanyo" => 64656 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Scree plot of the main components of the Overload Questionnaire for Carers of Patients on Peritoneal Dialysis.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Josep Teixidó-Planas, Laura Tarrats Velasco, Nieves Arias Suárez, Antonio Cosculluela Mas" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Josep" "apellidos" => "Teixidó-Planas" ] 1 => array:2 [ "nombre" => "Laura" "apellidos" => "Tarrats Velasco" ] 2 => array:2 [ "nombre" => "Nieves" "apellidos" => "Arias Suárez" ] 3 => array:2 [ "nombre" => "Antonio" "apellidos" => "Cosculluela Mas" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0211699518300432" "doi" => "10.1016/j.nefro.2018.02.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0211699518300432?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251418301111?idApp=UINPBA000064" "url" => "/20132514/0000003800000005/v1_201811140611/S2013251418301111/v1_201811140611/en/main.assets" ] "en" => array:18 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Reactivation of Hepatitis B virus in kidney transplant recipients with previous clinically resolved infection: A single-center experience" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "545" "paginaFinal" => "550" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Catarina Meng, Carolina Belino, Luciano Pereira, Ana Pinho, Susana Sampaio, Isabel Tavares, Manuela Bustorff, António Sarmento, Manuel Pestana" "autores" => array:9 [ 0 => array:4 [ "nombre" => "Catarina" "apellidos" => "Meng" "email" => array:1 [ 0 => "catarinameng@gmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Carolina" "apellidos" => "Belino" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 2 => array:3 [ "nombre" => "Luciano" "apellidos" => "Pereira" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "Ana" "apellidos" => "Pinho" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 4 => array:3 [ "nombre" => "Susana" "apellidos" => "Sampaio" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 5 => array:3 [ "nombre" => "Isabel" "apellidos" => "Tavares" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 6 => array:3 [ "nombre" => "Manuela" "apellidos" => "Bustorff" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 7 => array:3 [ "nombre" => "António" "apellidos" => "Sarmento" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 8 => array:3 [ "nombre" => "Manuel" "apellidos" => "Pestana" "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] ] "afiliaciones" => array:5 [ 0 => array:3 [ "entidad" => "Nephrology Department, Centro Hospitalar de São João, Porto, Portugal" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Nephrology and Infecciology Group, INEB/I3S, Porto, Portugal" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Nephrology Department, Centro Hospitalar de Vila Nova de Gaia-Espinho, Vila Nova de Gaia, Portugal" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Infectious Diseases Department, Centro Hospitalar de São João, Porto, Portugal" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Faculty of Medicine of University of Porto, Porto, Portugal" "etiqueta" => "e" "identificador" => "aff0025" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "<span class="elsevierStyleItalic">Corresponding author</span>." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Reactivación del virus de la hepatitis B en receptores de trasplante renal con infección previa resuelta clínicamente: una experiencia de un solo centro" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Hepatitis B virus (HBV) infection has decreased in frequency in kidney transplant recipients (KTR) due to the reinforcement of vaccination policies in the Chronic Kidney Disease (CKD) population and increased precautions to prevent transmission of the HBV among dialysis patients.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">1</span></a> Reactivation of HBV infection in KTR is associated with important morbidity and mortality.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">2</span></a> Immunosuppressive (IS) drugs used to prevent graft rejection blunt B and T cell functions and that permits HBV replication and viral protein expression on the surface of the infected hepatocytes.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">3</span></a> Reactivation is more frequent in patients who are HBsAg-positive, but it can also occur in patients with resolved HBV infection (HBsAg-negative and anti-HBc-positive), since the virus can still replicate within the hepatocytes.<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">4,5</span></a> Data are scarce and conflicting regarding the risk of HBV reactivation in this subset of patients. Reported rates of reactivation are variable; while some authors claim that the risk is negligible regardless of anti-HBs status,<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">6</span></a> others have published rates ranging from 1 to 6.5%.<a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">7,8</span></a> It has been suggested that in these patients the presence of anti-HBs antibodies may provide protection against HBV reactivation<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">8–10</span></a> but there are too few data about the proportion of renal transplant patients with resolved HBV infection and with positive anti-HBs titers that lose immunity during follow-up.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">11</span></a> Thus, it remains unclear regarding what kind of monitoring is needed and whether these patients would benefit from antiviral prophylaxis during the post-transplant period.</p><p id="par0010" class="elsevierStylePara elsevierViewall">In this study we aim to retrospectively evaluate the risk of HBV reactivation in KTR with previously resolved infection in a Portuguese Kidney Transplant Centre.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Material and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Study population</span><p id="par0015" class="elsevierStylePara elsevierViewall">We designed a retrospective cohort study enrolling all consecutive patients who underwent a kidney transplant at our center in the period between January 1994 and December 2014 who had serological evidence of resolved HBV infection at the time of transplantation. Patients were followed until September 30<span class="elsevierStyleSup">th</span>, 2015.</p><p id="par0020" class="elsevierStylePara elsevierViewall">Resolved HBV infection was defined as seropositivity for anti-HBc without detectable HBsAg, and normal liver enzymes (ALT, AST), with or without anti-HBs positive titers.</p><p id="par0025" class="elsevierStylePara elsevierViewall">Cutoff for positive anti-HBs was defined as >10<span class="elsevierStyleHsp" style=""></span>mIU/ml and loss of immunity was defined by fall of anti-HBs to levels bellow 10<span class="elsevierStyleHsp" style=""></span>mIU/ml and reactivation was defined according to current guidelines by a viral load >2000<span class="elsevierStyleHsp" style=""></span>IU/ml.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">12</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Exclusion criteria were: no information regarding viral status at the time of transplant, if they had a positive HBsAg, primary non-functioning allograft, and allograft survival less than 30 days.</p><p id="par0035" class="elsevierStylePara elsevierViewall">Acute rejection (BPAR) was defined by biopsy-proven histological changes compatible with either cellular or antibody-mediated rejection according to the latest Banff classification update available at the time of diagnosis.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Analyzed data</span><p id="par0040" class="elsevierStylePara elsevierViewall">Data were collected from the patients’ medical records. Demographic data included age, sex, time on dialysis, cause of CKD and number of previous transplants.</p><p id="par0045" class="elsevierStylePara elsevierViewall">Data regarding HBV serological status, IS regimen, use of antiviral prophylaxis, and occurrence of acute rejection were collected.</p><p id="par0050" class="elsevierStylePara elsevierViewall">In the evaluation of kidney transplant candidates and upon admission for renal transplant, liver enzymes (ALT, AST) and routine HBV serological markers were obtained from all transplant candidates. Our transplant center did not test HBV viral load in KTR with resolved HBV infection, and post-transplant serological HBV testing did not follow a systematic protocol, thus, the frequency of monitoring was left at the discretion of the attending Nephrologist. All patients’ post-transplant serological markers were recorded during the follow-up monitoring; the date of reactivation or the date of the last serological testing, whichever came first, was considered the end of follow-up. The follow-up appointments were scheduled according to our Institution's protocol but could be adjusted by the Nephrologist according to the patient's clinical status. Serological markers were obtained using hemi luminescent methods (Prism HBsAg<span class="elsevierStyleSup">®</span> and Prism HBcore<span class="elsevierStyleSup">®</span>, Abbott; Architect Anti-HBs<span class="elsevierStyleSup">®</span>, Abbott), and HBV DNA was obtained using multiplex nucleic acid test, COBAS<span class="elsevierStyleSup">®</span> TaqScreen MPX Test, version 2.0, Roche.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Statistical analysis</span><p id="par0055" class="elsevierStylePara elsevierViewall">Descriptive statistics were recorded as median and interquartile range (IQR) intervals. Univariate analysis was performed using Cox regression analysis; covariates with <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.1 were tested in a gender-adjusted multivariate model. Cox multiple regression analysis using the forward conditional method was performed to assess independent risk factors for loss of anti-HBs, and significance was considered if <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05. Statistical analysis was performed using IBM SPSS version 23 (IBM Corp. Released 2016. Armonk, NY: IBM Corp).</p></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Results</span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Patient data</span><p id="par0060" class="elsevierStylePara elsevierViewall">From the 1151 kidney transplant recipients performed during the study period the following were excluded: 137 without record of HBV serological status, 7 HBsAg-positive patients, 28 with primary graft failure and 13 patients with graft survival <30 days. From the remaining 966 patients, 867 were anti-HBc negative and the remaining 99 patients had evidence of resolved infection at the time of surgery.</p><p id="par0065" class="elsevierStylePara elsevierViewall">Four of the 99 patients had no information regarding post-transplant serological data and thus were excluded from the analysis. Of the remaining ninety-five patients, nine had anti-HBs <10<span class="elsevierStyleHsp" style=""></span>mIU/ml.</p><p id="par0070" class="elsevierStylePara elsevierViewall">Baseline characteristics of the study population are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Patient and graft survival</span><p id="par0075" class="elsevierStylePara elsevierViewall">Patients were followed at our Outpatient Clinic for a median time of 93 months (IQR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>58–146). Follow-up time did not differ significantly between patients who lost anti-HBs compared to those who did not (median follow-up time 68 vs 73 months, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.789). In patients who lost anti-HBs compared to those who did not 5 and 10 year patient survival rates were 93.9% and 89.9%, while 5 and 10 year allograft survival rates were 95.95% and 90.9%, respectively. During the study period, 13 patients died with a functioning allograft and 14 lost graft function.</p><p id="par0080" class="elsevierStylePara elsevierViewall">Seventeen cases of BPAR were recorded, nine of which were treated with pulses of metilprednisolone (MPD); 1 with MPD plus intravenous immunoglobulin, 5 with anti-thymocyte globulin (ATG) and 1 with MPD plus ATG. Treatment was not known in the remaining case.</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Immunosuppression</span><p id="par0085" class="elsevierStylePara elsevierViewall">IS regimens used at the time of transplantation and at the date of the last follow-up are presented in <a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>. Most patients were treated with a triple drug regimen; additionally, induction imunosuppression consisted of basiliximab in 30 patients (31.6%), ATG in 17 (17.9%) and daclizumab in 2 (2.1%).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0090" class="elsevierStylePara elsevierViewall">Twenty-one patients received ATG as induction therapy or as part of acute rejection treatment. At the end of follow-up all patients were on a low-dose steroid regimen consisting of 5<span class="elsevierStyleHsp" style=""></span>mg of prednisolone or equivalent per day.</p><p id="par0095" class="elsevierStylePara elsevierViewall">From the initial cohort of 99 patients, we were able to collect data regarding previous antiviral treatment on 88 patients (88.9%), confirming that none of those had been treated for HBV, having had spontaneous negativation of HBsAg.</p><p id="par0100" class="elsevierStylePara elsevierViewall">None of the patients had a history of HBV antiviral prophylaxis or use of rituximab.</p></span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Loss of immunity and reactivation</span><p id="par0105" class="elsevierStylePara elsevierViewall">During the time of follow-up 95 patients had 339 HBV serological tests, which corresponded to a median of 3 tests per patient (IQR 1–5), or 0.44 tests per patient-year. Twelve patients (13.9%) lost immunity and two patients (2%) showed evidence of reactivation.</p><p id="par0110" class="elsevierStylePara elsevierViewall">The first case was a 67 year-old male who had received a cadaveric allograft in 2007; at the time of transplantation anti-HBc and anti-HBs were positive (7.74 and 986<span class="elsevierStyleHsp" style=""></span>mUI/ml, respectively). Immunosuppression consisted of a triple regimen of cyclosporine, MMF (mycophenolate mofetil) and prednisolone. No major complications occurred until 2013, when he was admitted with a history of cough and weight loss. <span class="elsevierStyleItalic">Aspergilus fumigatus</span> was isolated in a Bronchoalveolar sample and itraconazol was started. Two weeks later, liver enzymes levels increased; itraconazol toxicity was suspected and the drug was stopped. HBV serological markers were compatible with reverse seroconversion with reappearance of HBsAg, and reactivation was diagnosed as the patient had a viral load of 1.7<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">8</span><span class="elsevierStyleHsp" style=""></span>IU/ml. Anti-HBs titer was 50.7<span class="elsevierStyleHsp" style=""></span>mUI/ml. Liver biopsy showed mild cholestasis, inflammatory infiltrate, ground-glass hepatocytes, nuclear expression of HBcAg and absence of HBsAg. The patient was started on entecavir, but expired a week later due to acute liver failure.</p><p id="par0115" class="elsevierStylePara elsevierViewall">The second patient was a 42 year-old male who had received its 3<span class="elsevierStyleSup">rd</span> transplant from a deceased donor in 2006; at the time of transplantation anti-HBc was 10.7<span class="elsevierStyleHsp" style=""></span>mIU/ml and anti-HBs was 2.67<span class="elsevierStyleHsp" style=""></span>mIU/ml. Induction immunosuppression included ATG and maintenance imunosuppression consisted of tacrolimus, MMF and prednisolone; baseline creatinine was 3.5<span class="elsevierStyleHsp" style=""></span>mg/dl. He was admitted with Pneumonia in 2014. Upon admission, liver enzymes were increased. HBV serological markers showed evidence of reverse seroconversion with reappearance of HBsAg, and reactivation was diagnosed as the patient had a viral load of 1.6<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleSup">4</span><span class="elsevierStyleHsp" style=""></span>IU/ml. Anti-HBs was 1.6<span class="elsevierStyleHsp" style=""></span>mIU/ml. Entecavir was started with disappearance of HBsAg and viremia, which became undetectable. At the time of discharge serum creatinine was 4<span class="elsevierStyleHsp" style=""></span>mg/dl. The patient lost his graft 10 months later due to chronic allograft nephropathy and restarted hemodialysis.</p><p id="par0120" class="elsevierStylePara elsevierViewall">Of the 12 patients who lost immunity during follow-up, the choice of IS drug did not seem to have any impact. Particularly, the use of MMF and use of ATG were not associated with loss of immunity (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.241 and 0.524, respectively) (<a class="elsevierStyleCrossRef" href="#tbl0015">table 3</a>). In the multivariate model adjusted for gender, older age (>60 years-old) was associated with loss of immunity (HR 4.853, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.024, CI [1.235; 19.071[) as was the presence of BPAR (HR 5.921, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.015, CI [1.416; 24.759[).</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia></span></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Discussion</span><p id="par0125" class="elsevierStylePara elsevierViewall">HBV reactivation is a potentially fatal condition with mortality rates reported as high as 25%.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">4</span></a> In our study the rate of HBV reactivation in patients with previously resolved infection was approximately 2%, resulting in death in one patient. This highlights the importance of assessing potential risk factors for reactivation since prophylaxis can prevent its occurrence.</p><p id="par0130" class="elsevierStylePara elsevierViewall">Only 4 retrospective studies addressed the risk of reactivation in HBsAg-negative and anti-HBc-positive KTR.<a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">7–9,13</span></a> The number of patients was small and reactivation rates varied from 0 to 6.5%. Risk factors for reactivation included older age, presence of rejection, use of rituximab and loss/absence of anti-HBs, but findings were not consistent among the 4 studies possibly due to the small number of cases in each study. We found that 13.9% of the patients with resolved HBV infection and positive anti-HBs titers lost immunity. In our series, older age and presence of BPAR were independent risk factors for loss of anti-HBs, which in its turn might increase the risk of reactivation. Age can be a risk factor since older patients tend to produce weaker immunological response and tend to have lower levels of anti-HBs.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a> Acute rejection is thought to be a risk factor through an increase of immunosuppression used for its treatment and this has been confirmed in other solid-organ transplants (SOT).<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a></p><p id="par0135" class="elsevierStylePara elsevierViewall">It is postulated that IS agents such as B-Cell depleting drugs like rituximab are associated with a high risk of HBV reactivation even in patients with resolved HBV infection.<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">4,13,14</span></a> In our study, none of our patients had received rituximab. Relationship between other drugs used in kidney transplantation and reactivation is less consistent.<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">8,15</span></a> We found no association between the type of IS drug used and loss of anti-HBs.</p><p id="par0140" class="elsevierStylePara elsevierViewall">Our study is limited by its retrospective nature, and we are unaware of when the patients included in our study acquired HBV infection and the timing of their acquisition of positive anti-HBs titers after the infection. We were also unable to assess previous HBV vaccination history. Both could influence anti-HBs titers and the risk of HBV reactivation after renal transplantation, although there are no studies addressing this issue.</p><p id="par0145" class="elsevierStylePara elsevierViewall">The retrospective nature of our study and the absence of HBV genotype testing in our reactivation cases do not allow us to completely rule out the possibility of re-infection instead of reactivation. However, both patients were diagnosed in an inpatient setting and none had recent history of high risk behavior or contact with blood products. Besides, both were highly immunosuppressed – one of the patients had a severe opportunistic infection and the other a high cumulative IS load given the history of 3 transplants, which favors the hypothesis of reactivation.</p><p id="par0150" class="elsevierStylePara elsevierViewall">Our transplant center did not test HBV viral load in KTR with resolved HBV infection, and serological HBV testing did not follow a systematic protocol. This way, we cannot assure that asymptomatic reactivations might have been missed during the follow-up period, and this way we might have underestimated the reactivation rates in our population. At last, the small number of reactivation cases did not allow us to infer about potential risk factors for reactivation. Our study however has some specific strengths; in an era of declining HBV incidence in the Western Countries, we have managed to retrieve a fairly high number of patients and a long term follow-up.</p><p id="par0155" class="elsevierStylePara elsevierViewall">The American Association for the Study of Liver Diseases recommends routine use of appropriate antiviral prophylaxis in all patients who are HBsAg-positive prior to or at the initiation of chemotherapy, immunosuppressive therapy, hematopoietic stem cell transplantation, or solid organ transplantation.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">12</span></a> When B-cell depleting agents like rituximab are used in patients with resolved infection (HBsAg-negative, anti-HBc-positive) antiviral prophylaxis can be anticipated to result in similar risk reduction of HBV reactivation as described for HBsAg-positive patients,<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">14</span></a> otherwise recommendations regarding antiviral prophylaxis in KTR with resolved HBV infection are lacking. Current guidelines do not recommend using anti-HBs titer to guide initiation of prophylaxis since there is no threshold level that universally prevents HBV reactivation.<a class="elsevierStyleCrossRefs" href="#bib0145"><span class="elsevierStyleSup">10,12,14</span></a> However, anti-HBs titer is still believed to confer protection against reactivation.<a class="elsevierStyleCrossRefs" href="#bib0135"><span class="elsevierStyleSup">8,13,16</span></a> Considering that loss of anti-HBs increases the risk of reactivation,<a class="elsevierStyleCrossRefs" href="#bib0130"><span class="elsevierStyleSup">7,8,17,18</span></a> patients who are at increased risk of anti-HBs loss, such as older patients and those with BPAR as found in our study, might benefit from closer surveillance of HBV DNA levels<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">4,10,19</span></a> or even antiviral prophylaxis. Although evidence is scarce regarding HBV DNA monitoring in patients with resolved HBV infection we suggest, as a cost-effective measure, a baseline measurement of HBV DNA levels for all candidates to kidney transplantation with resolved HBV infection (anti-HBc positive, HBsAg negative) to exclude occult viral replication. For those with positive HBV DNA we suggest antiviral prophylaxis starting from the time of transplantation and follow-up with periodical assessment of aminotransferases and HBV DNA levels. If the initial baseline HBV DNA is negative, we suggest serological HBV follow-up (HBsAg and anti-HBs) and close monitoring of aminotransferases levels. In case of HBsAg seroreversion or elevated aminotransferases, we suggest HBV DNA assessment. However, even with negative baseline negative HBV DNA; we acknowledge that some of these patients, especially if they are at higher risk of reactivation, might benefit from HBV DNA surveillance from the time of transplantation. In our study the small number of cases of HBV reactivation precludes any conclusion, and further studies are needed.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Conclusions</span><p id="par0160" class="elsevierStylePara elsevierViewall">In conclusion, the risk of HBV reactivation in KTR with previous clinically resolved infection is not negligible at 2%. Older age and acute rejection were associated with loss of anti-HBs, and these patients might benefit from closer surveillance of HBV DNA level. Routine serological and/or HBV viral load monitoring in HBsAg-negative, anti-HBc-positive patients is recommended and should be emphasized in these patients.</p></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Author contributions</span><p id="par0165" class="elsevierStylePara elsevierViewall">Meng C: design of study, data collection, drafting article. Belino C, Pereira L, Sampaio S, Tavares: data analysis, drafting article. Pinho A: critical revision and statistical analysis. Bustorff M: design of study, drafting and critical revision. Sarmento A and Pestana M: critical revision.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Conflict of interest</span><p id="par0170" class="elsevierStylePara elsevierViewall">The authors declare no conflict of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres1106902" "titulo" => "Abstract" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Objective" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Material and methods" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Results" ] 4 => array:2 [ "identificador" => "abst0025" "titulo" => "Conclusion" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1046360" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1106901" "titulo" => "Resumen" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "abst0030" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0035" "titulo" => "Objetivos" ] 2 => array:2 [ "identificador" => "abst0040" "titulo" => "Material y métodos" ] 3 => array:2 [ "identificador" => "abst0045" "titulo" => "Resultados" ] 4 => array:2 [ "identificador" => "abst0050" "titulo" => "Conclusión" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1046359" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Material and methods" "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Study population" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Analyzed data" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Statistical analysis" ] ] ] 6 => array:3 [ "identificador" => "sec0030" "titulo" => "Results" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "sec0035" "titulo" => "Patient data" ] 1 => array:2 [ "identificador" => "sec0040" "titulo" => "Patient and graft survival" ] 2 => array:2 [ "identificador" => "sec0045" "titulo" => "Immunosuppression" ] 3 => array:2 [ "identificador" => "sec0050" "titulo" => "Loss of immunity and reactivation" ] ] ] 7 => array:2 [ "identificador" => "sec0055" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0060" "titulo" => "Conclusions" ] 9 => array:2 [ "identificador" => "sec0065" "titulo" => "Author contributions" ] 10 => array:2 [ "identificador" => "sec0070" "titulo" => "Conflict of interest" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2017-09-07" "fechaAceptado" => "2018-02-08" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1046360" "palabras" => array:5 [ 0 => "Hepatitis B" 1 => "Kidney transplantation" 2 => "Infection" 3 => "Reactivation" 4 => "Risk factors" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1046359" "palabras" => array:5 [ 0 => "Hepatitis B" 1 => "Trasplante renal" 2 => "Infección" 3 => "Reactivación" 4 => "Factores de riesgo" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Background</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Hepatitis B virus (HBV) reactivation in kidney transplant recipients (KTR) involves important morbidity and mortality. Despite being more common in patients who are HBsAg-positive, it may occur in patients with clinically resolved infection (HBsAg-negative and anti-HBc-positive), in whom the presence of the protective anti-HB antibody is thought to decrease the risk of reactivation. Data regarding reactivation rates in this population are scarce.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Objective</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">To retrospectively evaluate the risk of HBV reactivation in KTR with previously resolved infection.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Material and methods</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Retrospective cohort study including patients who underwent a kidney transplant between January 1994 and December 2014 with resolved HBV infection at the time of transplantation (anti-HBc seropositivity without detectable HBsAg, with or without anti-HB-positive antibodies and normal liver enzymes).</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Results</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Out of 966 patients, 95 patients with evidence of resolved HBV infection were analyzed, of which 86 had a titer of anti-HBs >10<span class="elsevierStyleHsp" style=""></span>mIU/ml. Mean follow-up time was 93 months; 12 patients had lost anti-HBs. Two patients showed evidence of reactivation. Risk factors associated with loss of anti-HBs were elderly age (>60) and occurrence of acute graft rejection (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05).</p></span> <span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Conclusion</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">The risk of HBV reactivation in KTR with previously resolved infection is not negligible at 2%. Elderly age and acute rejection were associated with loss of anti-HBs, and these patients may benefit from closer monitoring of HBV DNA levels. Routine serology and/or HBV viral load monitoring in HBsAg-negative, anti-HBc-positive patients is recommended and should be emphasized in these patients.</p></span>" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Background" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Objective" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Material and methods" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Results" ] 4 => array:2 [ "identificador" => "abst0025" "titulo" => "Conclusion" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "<span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Introducción</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">La reactivación del virus de la hepatitis B (VHB) en receptores de trasplante renal (RTR) supone una importante morbilidad y mortalidad. A pesar de ser más frecuente en pacientes con HBsAg positivo, puede suceder en pacientes con infección clínicamente resuelta (HBsAg-negativo y anti-HBc-positivo). En estos casos, la presencia del anticuerpo protector anti-HBs parece disminuir el riesgo de reactivación. Existen escasos datos relativos a las tasas de reactivación en esta población.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Objetivos</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Evaluación retrospectiva del riesgo de reactivación del VHB en RTR con infección previa resuelta.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Material y métodos</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Estudio de cohorte retrospectivo, incluyendo RTR entre enero de 1994 y diciembre de 2014, con infección VHB resuelta en el momento del trasplante (anti-HBc seropositivo, HBsAg indetectable, con o sin anticuerpo anti-HBs e enzimas hepáticas normales).</p></span> <span id="abst0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Resultados</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">De un total de 966, 95 pacientes con evidencia de infección VHB resuelta fueron analizados; 86 tenían un título de anti-HBs<span class="elsevierStyleHsp" style=""></span>><span class="elsevierStyleHsp" style=""></span>10<span class="elsevierStyleHsp" style=""></span>mIU/ml. El tiempo medio de seguimiento fue de 93 meses, 12 pacientes habían perdido anti-HBs. Dos pacientes tuvieron evidencia de reactivación. Los factores de riesgo asociados a la pérdida de anti-HBs fueron la edad avanzada (>60) y la evidencia de rechazo agudo del injerto (p<span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0,05).</p></span> <span id="abst0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Conclusión</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">El riesgo de reactivación del VHB en RTR con infección previamente resuelta (2%) no es despreciable. La edad avanzada y el rechazo agudo están asociados a la pérdida de anti-HBs, y estos pacientes podrían beneficiarse de una vigilancia de los niveles de DNA del VHB. Las serologías de rutina y/o la monitorización de la carga viral en pacientes HBsAg-negativo, anti-HBc-positivo está recomendado y debería ser enfatizado en estos pacientes.</p></span>" "secciones" => array:5 [ 0 => array:2 [ "identificador" => "abst0030" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0035" "titulo" => "Objetivos" ] 2 => array:2 [ "identificador" => "abst0040" "titulo" => "Material y métodos" ] 3 => array:2 [ "identificador" => "abst0045" "titulo" => "Resultados" ] 4 => array:2 [ "identificador" => "abst0050" "titulo" => "Conclusión" ] ] ] ] "multimedia" => array:3 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Patient characteristics \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">N</span> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">Value \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Recipient age (years)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">50 [42–59] \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Recipient sex, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Male \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">33 (34.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Female \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">62 (65.3) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Cause of chronic kidney disease, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Glomerulonehpritis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">15 (15.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Polycystic kidney disease \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">14 (14.8) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Diabetic nephropathy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">11 (11.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Nephroangiosclerosis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8 (8.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>IgA nephropathy \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">8 (8.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Other \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">10 (10.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Unknown \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">29 (30.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Graft rank, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>First transplantation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">84 (88.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Retransplantation \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">11 (11.6) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Donor type, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Deceased \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">93 (97.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Living \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2 (2.1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Time on dialysis (months) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">38.5 [23.8–83.3] \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="3" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Type of dialysis, n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Hemodialysis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">86 (90.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Peritoneal dialysis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">9 (9.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1894074.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Baseline characteristics of the study population. Values are medians and interquartil ranges unless indicated otherwise.</p>" ] ] 1 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">CsA: ciclosporin A, TAC: tacrolimus, AZA: azathioprine, MMF: mofetil mycophenolate. During the follow-up period, 13 patients died and 14 lost their allograft and were therefore excluded.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">IS regimen \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">At the time of transplantation, <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>95 \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">At the end of follow-up, <span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>68 \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">TAC<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>MMF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>prednisolone, <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">34 (35.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">33 (48.5) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">CsA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>MMF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>prednisolone, <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">46 (48.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">26 (38.2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">CsA<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>Aza<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>prednisolone, <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">14 (14.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">2 (2.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Sirolimus<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>MMF<span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>prednisolone, <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">1 (1.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Everolimus <span class="elsevierStyleHsp" style=""></span>+<span class="elsevierStyleHsp" style=""></span>prednisolone, <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">4 (5.9) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Other, <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">3 (4.4) \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1894076.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Immunosuppressive regimens upon transplantation and at the end of follow-up.</p>" ] ] 2 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at3" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Variable \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">n</span> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">HR \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black">95% CI \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="center" valign="top" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> value \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">All patients</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Male gender</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">62 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.299 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.493–10.710 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.289 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Age >60</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">6.943 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.904–25.310 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.003 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Number of previous transplants >0</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.037 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.00–109.989 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.42 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Cause of CKD</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">95 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="" valign="top"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Diabetes</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " colspan="3" align="left" valign="top">Reference</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Hypertension</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.761 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.069–8.431 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.824 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Policystic kidney disease</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">14 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.276 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.226–7.214 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.783 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">IgA Nephropathy</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.678 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.61–7.486 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.751 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Glomerulonephritis</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.459 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.61–3.449 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.451 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleItalic">Other/Unknown</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">39 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">– \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="5" align="left" valign="top"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="table-entry " colspan="5" align="left" valign="top"><span class="elsevierStyleItalic">Induction imunossupression</span></td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>ATG vs none \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">16 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.636 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.075–5.392 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.468 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Basiliximab vs none \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">30 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3.975 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.960–16.461 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.057 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Use of ATG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">21 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">1.549 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.403–5.949 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.524 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Use of MMF \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">85 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">3.690 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">0.417–32.279 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.241 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top"><span class="elsevierStyleHsp" style=""></span>Biopsy-proven acute rejection \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">17 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">7.944 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">2.223–28.389 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="char" valign="top">0.001 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1894075.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Risk factors associated with loss of immunity (univariate analysis).</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:19 [ 0 => array:3 [ "identificador" => "bib0100" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Virus infection: epidemiology and vaccination" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C.W. Shepard" 1 => "E.P. Simard" 2 => "L. Finelli" 3 => "A.E. Fiore" 4 => "B.P. Bell" 5 => "B. Hepatitis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/epirev/mxj009" "Revista" => array:6 [ "tituloSerie" => "Epidemiol Rev" "fecha" => "2006" "volumen" => "28" "paginaInicial" => "112" "paginaFinal" => "125" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16754644" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0105" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "F. Fabrizi" 1 => "P. Martin" 2 => "V. Dixit" 3 => "F. Kanwal" 4 => "G. Dulai" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1600-6143.2005.01113.x" "Revista" => array:6 [ "tituloSerie" => "Am J Transplant" "fecha" => "2005" "volumen" => "5" "paginaInicial" => "2913" "paginaFinal" => "2921" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16303005" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0110" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.U. Neumann" 1 => "S. Phillips" 2 => "I. Levine" 3 => "S. Ijaz" 4 => "H. Dahari" 5 => "R. Eren" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Hepathology" "fecha" => "2010" "volumen" => "52" "paginaInicial" => "875" "paginaFinal" => "888" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0115" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A.M. Di Bisceglie" 1 => "A.S. Lok" 2 => "P. Martin" 3 => "N. Terrault" 4 => "R.P. Perrillo" 5 => "J.H. Hoofnagle" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.27609" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2015" "volumen" => "61" "paginaInicial" => "703" "paginaFinal" => "711" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25412906" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0120" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reactivation of hepatitis B" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "J.H. Hoofnagle" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.22945" "Revista" => array:7 [ "tituloSerie" => "Hepatology" "fecha" => "2009" "volumen" => "49" "numero" => "S5" "paginaInicial" => "S156" "paginaFinal" => "S165" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19399803" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0125" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Retrospective evaluation of the risk of hepatitis B virus reactivation after transplantation" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.T. Duhart Jr." 1 => "H.M. Shokouh-Amiri" 2 => "M.H. Riely" 3 => "C.A. Vera" 4 => "S.R. Taylor" 5 => "S.L. Al-jedai" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Transpl Infect Dis" "fecha" => "2003" "volumen" => "5" "paginaInicial" => "126" "paginaFinal" => "131" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14617300" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0130" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "N. Kanaan" 1 => "K.B. Maréchal" 2 => "C. Pirson" 3 => "Y. Beguin" 4 => "C. Goffin" 5 => "E.Z. Hassoun" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jcv.2012.07.015" "Revista" => array:6 [ "tituloSerie" => "J Clin Virol" "fecha" => "2012 Nov" "volumen" => "55" "paginaInicial" => "233" "paginaFinal" => "238" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22921412" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0135" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Outcomes and risk factors for hepatitis B virus (HBV) reactivation after kidney transplantation in occult HBV carriers" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "G.D. Chen" 1 => "G.J. Qiu" 2 => "J.L.Z. Chen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/tid.12065" "Revista" => array:6 [ "tituloSerie" => "Transpl Infect Dis" "fecha" => "2013" "volumen" => "15" "paginaInicial" => "300" "paginaFinal" => "305" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23473005" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0140" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "HBV reactivation after kidney transplantation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. Berger" 1 => "P.W. Kachel" 2 => "H.G. Stürmer" 3 => "M.H.W. Doerr" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jcv.2004.10.006" "Revista" => array:7 [ "tituloSerie" => "J Clin Virol" "fecha" => "2005" "volumen" => "32" "paginaInicial" => "162" "paginaFinal" => "165" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15653420" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0002939407008021" "estado" => "S300" "issn" => "00029394" ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0145" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "EASL clinical practice guidelines: management of chronic hepatitis B virus infection" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "European Association for the Study of the Liver" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2012.02.010" "Revista" => array:7 [ "tituloSerie" => "J Hepatol" "fecha" => "2012" "volumen" => "57" "paginaInicial" => "167" "paginaFinal" => "185" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22436845" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0886335010015683" "estado" => "S300" "issn" => "08863350" ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0150" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "A. Knoll" 1 => "M. Pietrzyk" 2 => "M. Loss" 3 => "W.A. Goetz" 4 => "W. Jilg" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:7 [ "tituloSerie" => "Transplantation" "fecha" => "2005" "volumen" => "79" "paginaInicial" => "1631" "paginaFinal" => "1633" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15940056" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0886335010000891" "estado" => "S300" "issn" => "08863350" ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0155" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "AASLD guidelines for treatment of chronic hepatitis B" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "N.A. Terrault" 1 => "N.H. Bzowej" 2 => "K.-M. Chang" 3 => "J.P. Hwang" 4 => "M.M. Jonas" 5 => "M.H. Murad" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.28156" "Revista" => array:6 [ "tituloSerie" => "Hepatology" "fecha" => "2016" "volumen" => "63" "paginaInicial" => "261" "paginaFinal" => "283" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26566064" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0160" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:3 [ "comentario" => "906-906" "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rituximab and hepatitis B reactivation in HBsAg-negative/anti-HBc-positive kidney transplant recipients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Lee" 1 => "J.Y. Park" 2 => "K.H. Huh" 3 => "B.S. Kim" 4 => "M.S. Kim" 5 => "S.I. Kim" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:3 [ "tituloSerie" => "Nephrol Dial Transplant" "fecha" => "2017" "volumen" => "32" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0165" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "K.R. Reddy" 1 => "K.L. Beavers" 2 => "S.P. Hammond" 3 => "J.K. Lim" 4 => "Y.T. Falck-Ytter" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.gastro.2014.10.039" "Revista" => array:6 [ "tituloSerie" => "Gastroenterology" "fecha" => "2015" "volumen" => "148" "paginaInicial" => "215" "paginaFinal" => "219" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25447850" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0170" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Management of hepatitis B reactivation in immunosuppressed patients: an update on current recommendations" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "F.D.M. Bessone" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4254/wjh.v8.i8.385" "Revista" => array:6 [ "tituloSerie" => "World J Hepatol" "fecha" => "2016" "volumen" => "8" "paginaInicial" => "385" "paginaFinal" => "394" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27004086" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0175" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "R.P. Perrillo" 1 => "R. Gish" 2 => "Y.T. Falck-Ytter" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1053/j.gastro.2014.10.038" "Revista" => array:6 [ "tituloSerie" => "Gastroenterology" "fecha" => "2015" "volumen" => "148" "paginaInicial" => "221" "paginaFinal" => "244000" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25447852" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0180" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C. Hsu" 1 => "T.H. Lin" 2 => "S.J. Wang" 3 => "M.C. Yao" 4 => "M. Hwang" 5 => "W.L. Kao" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.26718" "Revista" => array:5 [ "tituloSerie" => "Hepatology" "fecha" => "2014" "volumen" => "59" "paginaInicial" => "2092" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24002804" "web" => "Medline" ] ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0185" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "W. Yeo" 1 => "C.T. Leung" 2 => "N.W. Lam" 3 => "W.Y. Mo" 4 => "F.K. Chu" 5 => "M.T. Chan" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1200/JCO.2008.18.0182" "Revista" => array:5 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2009" "volumen" => "27" "paginaInicial" => "605" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19075267" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0190" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The difficulties of managing severe hepatitis B virus reactivation" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "B. Roche" 1 => "D. Samuel" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1478-3231.2010.02396.x" "Revista" => array:6 [ "tituloSerie" => "Liver Int" "fecha" => "2011" "volumen" => "31" "paginaInicial" => "104" "paginaFinal" => "110" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21205146" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003800000005/v1_201811140611/S2013251418301159/v1_201811140611/en/main.assets" "Apartado" => array:4 [ "identificador" => "42660" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003800000005/v1_201811140611/S2013251418301159/v1_201811140611/en/main.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2013251418301159?idApp=UINPBA000064" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 11 | 4 | 15 |
| 2024 October | 65 | 45 | 110 |
| 2024 September | 64 | 25 | 89 |
| 2024 August | 75 | 78 | 153 |
| 2024 July | 59 | 25 | 84 |
| 2024 June | 90 | 44 | 134 |
| 2024 May | 74 | 25 | 99 |
| 2024 April | 72 | 41 | 113 |
| 2024 March | 78 | 27 | 105 |
| 2024 February | 60 | 43 | 103 |
| 2024 January | 61 | 21 | 82 |
| 2023 December | 64 | 27 | 91 |
| 2023 November | 67 | 33 | 100 |
| 2023 October | 118 | 30 | 148 |
| 2023 September | 85 | 32 | 117 |
| 2023 August | 74 | 21 | 95 |
| 2023 July | 94 | 25 | 119 |
| 2023 June | 91 | 18 | 109 |
| 2023 May | 91 | 60 | 151 |
| 2023 April | 64 | 28 | 92 |
| 2023 March | 73 | 23 | 96 |
| 2023 February | 81 | 23 | 104 |
| 2023 January | 57 | 27 | 84 |
| 2022 December | 93 | 30 | 123 |
| 2022 November | 84 | 29 | 113 |
| 2022 October | 79 | 49 | 128 |
| 2022 September | 93 | 35 | 128 |
| 2022 August | 112 | 46 | 158 |
| 2022 July | 73 | 45 | 118 |
| 2022 June | 101 | 38 | 139 |
| 2022 May | 82 | 33 | 115 |
| 2022 April | 60 | 56 | 116 |
| 2022 March | 89 | 44 | 133 |
| 2022 February | 69 | 49 | 118 |
| 2022 January | 57 | 56 | 113 |
| 2021 December | 66 | 41 | 107 |
| 2021 November | 67 | 40 | 107 |
| 2021 October | 98 | 55 | 153 |
| 2021 September | 51 | 27 | 78 |
| 2021 August | 51 | 49 | 100 |
| 2021 July | 76 | 33 | 109 |
| 2021 June | 40 | 40 | 80 |
| 2021 May | 44 | 43 | 87 |
| 2021 April | 175 | 69 | 244 |
| 2021 March | 81 | 53 | 134 |
| 2021 February | 98 | 22 | 120 |
| 2021 January | 92 | 40 | 132 |
| 2020 December | 60 | 25 | 85 |
| 2020 November | 72 | 31 | 103 |
| 2020 October | 49 | 24 | 73 |
| 2020 September | 62 | 24 | 86 |
| 2020 August | 66 | 15 | 81 |
| 2020 July | 42 | 21 | 63 |
| 2020 June | 55 | 16 | 71 |
| 2020 May | 91 | 31 | 122 |
| 2020 April | 48 | 31 | 79 |
| 2020 March | 95 | 17 | 112 |
| 2020 February | 67 | 25 | 92 |
| 2020 January | 95 | 36 | 131 |
| 2019 December | 91 | 28 | 119 |
| 2019 November | 68 | 25 | 93 |
| 2019 October | 60 | 25 | 85 |
| 2019 September | 63 | 17 | 80 |
| 2019 August | 59 | 26 | 85 |
| 2019 July | 56 | 35 | 91 |
| 2019 June | 70 | 38 | 108 |
| 2019 May | 52 | 40 | 92 |
| 2019 April | 63 | 51 | 114 |
| 2019 March | 31 | 24 | 55 |
| 2019 February | 40 | 27 | 67 |
| 2019 January | 37 | 40 | 77 |
| 2018 December | 67 | 45 | 112 |
| 2018 November | 38 | 10 | 48 |
Show all
